| Titolo |
Pubblicato in |
Anno |
| COVID-19 vaccination in cancer patients: Immune responses one year after the third dose |
VACCINE |
2024 |
| Testicular ultrasonographic features predict future risk for bilateral testicular germ cell tumour: A long-term single centre follow-up study |
ANDROLOGY |
2024 |
| Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) |
NPJ BREAST CANCER |
2024 |
| Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach |
CANCER IMMUNOLOGY, IMMUNOTHERAPY |
2023 |
| Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer |
FRONTIERS IN ONCOLOGY |
2023 |
| NmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives |
CANCER TREATMENT REVIEWS |
2023 |
| Lenvatinib Versus Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis |
ANTICANCER RESEARCH |
2023 |
| Predictive role of diffusion-weighted MRI in the assessment of response to total neoadjuvant therapy in locally advanced rectal cancer |
EUROPEAN RADIOLOGY |
2023 |
| The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management |
FRONTIERS IN ONCOLOGY |
2023 |
| Oncology-Led Early Identification of Nutritional Risk: A Pragmatic, Evidence-Based Protocol (PRONTO) |
CANCERS |
2023 |
| Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer |
CELLS |
2023 |
| The management of oligometastatic disease in colorectal cancer: present strategies and future perspectives |
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY |
2023 |
| Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge |
BIOMEDICINES |
2023 |
| Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study |
CANCERS |
2023 |
| Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia |
CANCERS |
2023 |
| Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials |
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY |
2023 |
| Selective Internal Radiation Therapy (SIRT): a new emerging role for Breast Cancer Liver Metastases |
TUMORI |
2023 |
| Circulating CD137+ T cell subsets and MDCSs as immune biomarkers for response to anti-PD1 immunotherapy in NSCLC patients |
AICC INTERNATIONAL MEETING – TRANSLATIONAL AND PRECISION MEDICINE |
2023 |
| Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study |
FRONTIERS IN ONCOLOGY |
2023 |
| Angiogenic factors as prognostic markers in neuroendocrine neoplasms |
ENDOCRINE |
2022 |
